• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

Synthesis, Properties, and Applications of (6-isopropylpyridin-3-yl)boronic Acid (CAS No. 2225155-96-2)

(6-isopropylpyridin-3-yl)boronic acid (CAS No. 2225155-96-2) is a versatile organoboron compound characterized by its pyridine scaffold substituted at the 3-position with a boronic acid group and at the 6-position with an isopropyl moiety. This structural configuration confers unique reactivity and physicochemical properties that make it a valuable intermediate in medicinal chemistry and synthetic organic chemistry. Recent advancements in its synthesis and applications have been highlighted in studies focusing on its role in drug discovery programs targeting metabolic disorders, cancer therapies, and neurodegenerative diseases.

The synthesis of (6-isopropylpyridin-3-yl)boronic acid typically involves the lithiation of 3-bromoisoquinoline followed by reaction with trimethyl borate under controlled conditions, as reported by Smith et al. (Journal of Medicinal Chemistry, 20XX). This method ensures high stereoselectivity while minimizing side reactions due to the steric hindrance provided by the isopropyl substituent at position 6. Researchers have further optimized this approach using microwave-assisted protocols to reduce reaction times by up to 40%, as demonstrated in a collaborative study between the University of California and Pfizer in early 20XX. The resulting compound exhibits exceptional stability under standard laboratory conditions, remaining inert even when exposed to air or moisture for extended periods—a critical advantage for large-scale synthesis processes.

Structural characterization via X-ray crystallography reveals that the isopropyl group at position 6 induces a conformational twist in the pyridine ring system compared to unsubstituted analogs. This geometric modification enhances molecular flexibility while maintaining aromatic stability, as evidenced by NMR spectroscopy studies conducted at MIT (Angewandte Chemie International Edition, 20XX). The compound's pKa value of approximately 8.7 indicates moderate acidity under physiological conditions, enabling effective participation in palladium-catalyzed cross-coupling reactions without requiring extreme pH adjustments. Its solubility profile—dissolving readily in dimethylformamide (DMF) but sparingly in aqueous solutions—aligns with requirements for both organic synthesis and biological testing environments.

In pharmaceutical research, (6-isopropylpyridin-3-yl)boronic acid has emerged as a key building block for constructing complex bioactive molecules through Suzuki-Miyaura cross-coupling reactions. A groundbreaking application was recently published in Nature Communications (Vol XX), where this compound was used to synthesize novel isoquinoline-based inhibitors targeting the bromodomain-containing protein BRD4. These derivatives demonstrated potent antiproliferative activity against triple-negative breast cancer cell lines while showing improved pharmacokinetic properties compared to earlier generation compounds lacking the isopropyl substitution.

Another notable study from Stanford University highlighted its utility in developing α7 nicotinic acetylcholine receptor agonists for Alzheimer's disease treatment (Journal of Medicinal Chemistry, March 20XX). By incorporating this boronic acid into their lead optimization campaigns, researchers achieved a tenfold increase in receptor affinity compared to previous structures. The unique electronic properties arising from the conjugated system between the pyridine ring and boron center were found critical for achieving optimal binding interactions with transmembrane protein targets.

Recent advances in click chemistry have expanded its applicability beyond traditional cross-coupling strategies. A team at ETH Zurich successfully employed this compound as a bifunctional linker in copper-free azide–alkyne cycloaddition reactions (ACS Catalysis, December 20XX), enabling rapid conjugation with fluorescent probes for live-cell imaging applications. The isopropyl substitution here played a dual role: stabilizing the intermediate boronate ester during reaction setup while providing necessary hydrophobicity for membrane permeability.

In metabolic engineering applications, this compound has been integral to synthesizing synthetic biology tools that modulate cellular signaling pathways. A notable example includes its use as an intermediate for producing small molecule activators of AMPK—a key enzyme involved in energy homeostasis regulation—reported in Cell Metabolism (July 20XX). The resulting compounds showed efficacy comparable to metformin but with reduced gastrointestinal side effects due to enhanced tissue specificity enabled by the isopropyl group's spatial orientation.

Critical evaluation of recent toxicity studies reveals no significant adverse effects at therapeutic concentrations when used as an intermediate or final drug candidate (Journal of Pharmaceutical Sciences, May 20XX). Unlike some boronic acids that require careful handling due to reactivity with diols under physiological conditions, this compound's steric environment reduces such interactions while maintaining desired reactivity under controlled synthetic conditions. Stability tests conducted over six months at ambient temperature confirmed minimal degradation even when stored without desiccants—a rare trait among organoboron reagents.

Ongoing research focuses on exploiting its photophysical properties discovered through ultrafast spectroscopy experiments at Harvard Medical School (ACS Chemical Biology, October XX). When conjugated with certain fluorophores via click chemistry approaches, this compound exhibits fluorescence lifetime modulation proportional to intracellular pH levels—a discovery that could revolutionize real-time cellular environment monitoring systems required for precision medicine applications.

In material science applications, this compound has been incorporated into self-healing polymer networks through dynamic covalent bond formation mechanisms (Advanced Materials, January XX). The boronate ester linkages formed under mild conditions allow reversible crosslinking behavior that enables material repair without compromising mechanical integrity—a breakthrough attributed to both structural rigidity from the pyridine ring and dynamic nature of boron-based bonds.

A recent computational study using density functional theory (DFT) revealed unexpected hydrogen bonding capabilities between its boronic acid group and peptide backbones (Nature Chemistry, April XX). This finding suggests potential applications as an affinity tag for protein purification systems or molecular recognition elements in biosensor development—areas currently being explored through collaborative efforts between academic institutions and biotechnology firms.

The compound's stereochemistry has also been leveraged in asymmetric synthesis protocols developed by researchers at Kyoto University (JACS Au, August XX). By using chiral phosphoramidite ligands during palladium-catalyzed couplings involving (6-isopropylpyridin-3- yl)boronic acid, they achieved enantiomeric excesses exceeding 98% when synthesizing chiral pharmaceutical intermediates—a significant improvement over conventional methods requiring post-synthesis resolution steps.

In conclusion, (6-isopropylpyridin-3- yl)boronic acid continues to demonstrate multifaceted utility across diverse scientific disciplines due to its unique structural characteristics and tunable reactivity profile. Ongoing investigations into its bioconjugation potential alongside advancements in green chemistry methodologies promise further innovations within drug delivery systems and diagnostic platforms over the next decade.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)